Please assess the completion status of the following clinical trial:

Trial Title: Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Microangiopathic hemolytic anemia (\< 12 g/dL) with thrombocytopenia \<50 G/L, and mild or no renal failure (Serum creatinine \< 150 µmol/L),~* negative Beta HCG and ongoing contraception during treatment and during the 24 months following the last infusion of rituximab,~* refractory TTP (after 4 days of standard treatment)~* \> 18 year old~* and signed written informed consent.~Exclusion Criteria:~* Hemolytic uremic syndrome (platelet count ³ 50 G/L and serum creatinine ³ 150 micromol/L),~* TTP associated with another condition (HIV infection, cancer and/or chemotherapy, transplantation),~* previous treatment with vincristine or cyclophosphamide or other immunomodulatory drugs (except steroids), within 2 months before inclusion ;~* ongoing or planned pregnancy, lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Microangiopathic hemolytic anemia (\< 12 g/dL) with thrombocytopenia (\<50 G/L)

Based on this trial design, predict the completion outcome and termination type (if applicable).